Wells Fargo’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-76
Closed – – 6732
2017
Q2
$0 Buy
76
+20
+36% +$9 ﹤0.01% 6769
2017
Q1
$0 Hold
56
– – ﹤0.01% 6792
2016
Q4
$0 Buy
56
+4
+8% +$2 ﹤0.01% 6732
2016
Q3
$0 Sell
52
-6
-10% -$2 ﹤0.01% 6644
2016
Q2
$0 Buy
+58
New +$30 ﹤0.01% 6734

Wells Fargo's AST.WS Position: Q3 2017 in Review

Wells Fargo sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 76 shares.

Wells Fargo first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Wells Fargo reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Wells Fargo sold 76 Asterias Biotherapeutics Warrants shares in Q3 2017.
  • Wells Fargo first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • Wells Fargo's Asterias Biotherapeutics Warrants position peaked at $0 in Q2 2017.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Wells Fargo's 13F filing for Q3 2017, filed 9 Nov 2017.